<DOC>
	<DOCNO>NCT02844270</DOCNO>
	<brief_summary>The Galaxy First-in-man study small pilot . single arm research , enroll total 45 patient . The goal access feasibility , safety efficacy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System treatment patient de novo coronary lesion .</brief_summary>
	<brief_title>Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System First-in-man Study</brief_title>
	<detailed_description>This study prospective , single arm clinical trial . 45 patient enrol study randomly assign queue1 ( n=30 ) queue 2 ( n=15 ) . The clinical follow-up perform subject 1 month,6 months,1 year,2 years,3 years,4 year 5 year stent implantation ; angiographic , IVUS OCT follow-up perform 6 month 2 year stent implantation queue 1 ; angiographic , IVUS OCT follow-up perform 1 year 3 year stent implantation queue 2 . The primary endpoint study target lesion failure ( TLF ) 30 day stent implantation .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1875 year age , male nonpregnant female ; With silent ischemia evidence , patient stable unstable angina , patient old myocardial infarction ; Total number target lesion 1 ; Target lesion must ≤ 25mm length ( visual estimation ) 3.0 3.75 mm diameter ; Visual assessment target lesion diameter stenosis ≥ 70 % , TIMI blood flow≥1 ; The target lesion cover one stent ; Patient must acceptable candidate coronary artery bypass graft ; To understand purpose testing , voluntary inform consent , patient undergo invasive imaging followup . Within 1 week acute myocardial infarction myocardial enzymes return normal ; Implantation stent target vessel within 1 year , patient plan intervention within six month ; Severe congestive heart failure ( NYHA class III ) , leave ventricular ejection fraction &lt; 40 % ( ultrasound leave ventricular angiography ) ; Preoperative renal function serum creatinine &gt; 2.0mg/DL ; receive hemodialysis ; Bleeding , active gastrointestinal ulcer , brain hemorrhage subarachnoid hemorrhage half year history ischemic stroke , antiplatelet agent would allow anticoagulant therapy contraindication patient undergo antithrombotic therapy ; Aspirin , clopidogrel , heparin , contrast agent , poly lactic acid polymer rapamycin allergy ; The patient 's life expectancy le 12 month ; To participate drug medical device meet primary study endpoint clinical trial time frame ; Researchers determine patient compliance poor , unable complete study accordance requirement ; Heart transplantation patient ; The unstable arrhythmia , high risk ventricular extrasystole ventricular tachycardia ; Cancer need chemotherapy ; Immunosuppression autoimmune disease , plan undergoing immunosuppressive therapy ; Planning receive longterm anticoagulant therapy , heparin , warfarin , etc ; Within six month elective surgery require stop aspirin , Clopidogrel patient ; Blood test prompt platelet count less 100x10E9/L great 700x10E9/L , white blood cell 3x10E9/L ; know suspect liver disease ( hepatitis ) ; Peripheral vascular disease , 6F catheter available .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>